Article: CDC Advisory Committee on Immunization Practices Votes for Permissive Use and for Vaccines for Children Funding for GARDASIL[R] for Boys and Young Men.

Merck & Co., Inc. announced that the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) supports the permissive use of GARDASIL[R] [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for boys and young men ages 9 to 26, which means that GARDASIL may be given to males ages 9 to 26 to reduce the likelihood of acquiring genital warts at the discretion of the patient's health care provider. The ACIP also voted to recommend that funding be provided for the use of GARDASIL in males through the Vaccines for Children (VFC) program (see also MERCK & CO., Inc.).

On October 16, the ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!